نتایج جستجو برای: melphalan

تعداد نتایج: 4419  

1988
Stephen X. Skapek O. Michael Colvin Owen W. Griffith Gertrude B. Elion Dardi D. Bigner Henry S. Friedman

The effect and therapeutic consequences of buthionim--(.S'A)-sulfoximine (BSO)-inediated depletion of glutathione in the human medulloblastoma-derived cell line, TE-671, growing as s.c. xenografts in athymic nude mice were examined. The glutathione content of the s.c. xenografts was 1.11 ±0.15(imol/g(7.79± 1.61 nmol/mgof protein). Administration i.p. to tumor-bearing mice of n.i.-BSO (two dos...

Journal: :Cancer research 1977
G J Goldenberg M Lee H Y Lam A Begleiter

Mechanism of transport of the alkylating agent [14C]melphalan was investigated in L5178Y lymphoblasts in vitro. A time course of melphalan uptake was approximately linear for 5 to 10 min and thereafter entered a plateau region. Evidence that unidirectional influx of melphalan is carrier mediated was that uptake obeyed simple Michaelis-Menten kinetics, that it demonstrated chemical specificity, ...

Journal: :Cancer research 2003
Lori A Hazlehurst Steven A Enkemann Craig A Beam Raul F Argilagos Jeffrey Painter Kenneth H Shain Sara Saporta David Boulware Lynn Moscinski Melissa Alsina William S Dalton

Cancer cell adhesion confers a transient, de novo drug-resistant phenotype referred to as cell adhesion-mediated drug resistance (CAM-DR). In this report, we extend the CAM-DR phenotype to primary specimens from patients with myeloma, providing further evidence that CAM-DR is a viable clinical form of drug resistance. To examine mechanisms of cellular resistance to melphalan, we compared genoty...

Journal: :Lancet 2007
Thierry Facon Jean Yves Mary Cyrille Hulin Lotfi Benboubker Michel Attal Brigitte Pegourie Marc Renaud Jean Luc Harousseau Gaëlle Guillerm Carine Chaleteix Mamoun Dib Laurent Voillat Hervé Maisonneuve Jacques Troncy Véronique Dorvaux Mathieu Monconduit Claude Martin Philippe Casassus Jérôme Jaubert Henry Jardel Chantal Doyen Brigitte Kolb Bruno Anglaret Bernard Grosbois Ibrahim Yakoub-Agha Claire Mathiot Hervé Avet-Loiseau

BACKGROUND In multiple myeloma, combination chemotherapy with melphalan plus prednisone is still regarded as the standard of care in elderly patients. We assessed whether the addition of thalidomide to this combination, or reduced-intensity stem cell transplantation, would improve survival. METHODS Between May 22, 2000, and Aug 8, 2005, 447 previously untreated patients with multiple myeloma,...

2015
Kamila Anna Zub Mirta Mittelstedt Leal de Sousa Antonio Sarno Animesh Sharma Aida Demirovic Shalini Rao Clifford Young Per Arne Aas Ida Ericsson Anders Sundan Ole Nørregaard Jensen Geir Slupphaug

Alkylating agents are widely used chemotherapeutics in the treatment of many cancers, including leukemia, lymphoma, multiple myeloma, sarcoma, lung, breast and ovarian cancer. Melphalan is the most commonly used chemotherapeutic agent against multiple myeloma. However, despite a 70-80% initial response rate, virtually all patients eventually relapse due to the emergence of drug-resistant tumour...

Journal: :Blood 2011
Francesca Gay Alessandra Larocca Pierre Wijermans Federica Cavallo Davide Rossi Ron Schaafsma Mariella Genuardi Alessandra Romano Anna Marina Liberati Agostina Siniscalchi Maria T Petrucci Chiara Nozzoli Francesca Patriarca Massimo Offidani Roberto Ria Paola Omedè Benedetto Bruno Roberto Passera Pellegrino Musto Mario Boccadoro Pieter Sonneveld Antonio Palumbo

Complete response (CR) was an uncommon event in elderly myeloma patients until novel agents were combined with standard oral melphalan-prednisone. This analysis assesses the impact of treatment response on progression-free survival (PFS) and overall survival (OS). We retrospectively analyzed 1175 newly diagnosed myeloma patients, enrolled in 3 multicenter trials, treated with melphalan-predniso...

Journal: :Cancer research 1991
E R Lilley G B Elion M W Dewhirst S C Schold M R Blum P M Savina D T Laskowitz D D Bigner H S Friedman

Investigations with the melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR were carried out to identify patterns of cross-resistance and collateral sensitivity and to define the mechanism(s) mediating melphalan resistance. TE-671 MR was cross-resistant to thio-TEPA, mitomycin, vincristine, and cisplatin, and partially resistant to chlorambucil and cyclophosphamide. TE-671 MR and the...

2014
Jasmine H. Francis David H. Abramson Y. Pierre Gobin Brian P. Marr Ira J. Dunkel Elyn R. Riedel Scott E. Brodie

PURPOSE To report electroretinogram responses of retinoblastoma children under anesthesia before and after treatment with chemotherapeutic drugs (melphalan, topotecan, carboplatin) delivery by ophthalmic artery chemosurgery (OAC). METHODS A cohort study of 81 patients with retinoblastoma treated with OAC. All patients treated with OAC at our center through May 2012 for whom the requisite ERG ...

Journal: :Cancer research 1987
J Hansson R Lewensohn U Ringborg B Nilsson

The formation and removal of nitrogen mustard (HN2)- and melphalan-induced DNA cross-links (DNA interstrand and DNA-protein cross-links) in a human melanoma cell line (RPMI 8322), as determined by alkaline elution of DNA, was compared and related to the cytotoxic effect of each drug. HN2 was considerably more cytotoxic than melphalan as determined by inhibition of colony formation. Immediately ...

2006
Lawrence C. Panasci Jonathan Bramson

Previous studies of ERCC-1 gene expression levels in chronic lymphocytic leukemia and ovarian carcinoma tumor specimens indicated that increased gene expression may correlate with a lack of response to the alkylating agents, melphalan, and cu-diamminedichloroplatinum (II). In order to demonstrate direct involvement of the ERCC-1 protein in repair of melphalan lesions, the ERCC-1 defective Chine...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید